{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-138946","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.885319+00:00","generated_at":"2026-06-15T09:21:14.709060+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Verrica Q1 net loss narrows to $6.6M; raised $32.5M; YCANTH PDUFA July 23, 2023","bullets":["Net loss of $6.6M ($0.15 GAAP EPS) vs $8.5M ($0.31) in Q1 2022; non-GAAP net loss $5.5M ($0.13).","Cash and equivalents $60.0M as of March 31, 2023; management expects runway into Q1 2024.","PDUFA goal date of July 23, 2023 for YCANTH (VP-102) for molluscum contagiosum; no FDA-approved therapy exists.","Raised $32.5M gross proceeds in February 2023 underwritten offering to support pre-commercial activities and VP-315 trial.","VP-315 advanced into Part 2 of Phase 2 study for basal cell carcinoma; Part 3 expected to start first half 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-138946","json":"https://secwatch.observer/filing/0001193125-23-138946.json","markdown":"https://secwatch.observer/filing/0001193125-23-138946.md","text":"https://secwatch.observer/filing/0001193125-23-138946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523138946/0001193125-23-138946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523138946/d429426d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:21:14.709060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"992c278d134067cbaa0e626f82ddf931340da99e","claim":"Verrica Pharmaceuticals Inc. reported the first quarter ended March 31, 2023 results: revenue $37,000, net income $6.6 million, EPS $0.15 per share.","evidence_excerpt":"million underwritten offering of common stock and pre-funded warrants. Financial Results First Quarter 2023 Financial Results • Verrica recognized collaboration revenues of $37,000 in the first quarter of 2023 compared to $0.4 million for the same period in 2022 related to the Collaboration and License Agreement with Torii Pharmaceutical Col, Ltd (“Torii”).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523138946/0001193125-23-138946-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$37,000"},{"label":"Net income","value":"$6.6 million"},{"label":"EPS","value":"$0.15 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}